---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-000137"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2024-01-24T23:59:59+00:00"
generated_at: "2026-06-06T19:09:00.234668+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Lexaria CEO provides 2024 outlook; GLP-1 pilot shows DehydraTECH semaglutide benefit; IND filing imminent

## Summary
- Stock recovered above $1, avoiding reverse split; October capital raise on less punitive terms.
- DehydraTECH semaglutide pilot (7 subjects) showed statistically higher drug proportion, faster absorption, fewer side effects vs Rybelsus.
- FDA IND application for hypertension delayed ~5 months due to supplier; submission expected soon.
- No debt taken in 2023 and no plan for debt in 2024; institutional holders rose to 19 with 1.8M shares.
- R&D highlights: catestatin, inflammatory biomarkers, weight loss, blood glucose reduction, and nicotine study beating Zyn/On.

## SEC filing metadata
- accession: 0001640334-24-000137
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2024-01-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000137/0001640334-24-000137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000137/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-000137
- JSON: https://secwatch.observer/filing/0001640334-24-000137.json
- Plain text: https://secwatch.observer/filing/0001640334-24-000137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.